Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

Rival drugmakers launch joint trial of medicines for COVID-19

share with twitter share with LinkedIn share with facebook
08/03/2020 | 06:06am EDT
FILE PHOTO: A computer image created by Nexu Science Communication together with Trinity College in Dublin, shows a model structurally representative of a betacoronavirus which is the type of virus linked to COVID-19

Rival drugmakers AbbVie Inc, Amgen Inc and Takeda Pharmaceuticals Inc on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavirus.

The COVID-19 pandemic is an "all hands on deck moment," David Reese, Amgen's research and development chief told Reuters. "We wanted a trial to be able to quickly sift through multiple agents and prioritize."

The study is a collaboration among pharmaceutical industry members of the recently-formed COVID Research & Development Alliance, Quantum Leap Healthcare Collaborative, a partnership of medical researchers and investors, and the Food and Drug Administration.

The first segment will test whether Amgen's psoriasis drug Otezla, Takeda's anti-inflammatory Firazyr and AbbVie's cenicriviroc, which has been tried in patients with HIV, will help with the overactive, and potentially damaging, immune response that sometimes happens in patients with severe COVID-19.

The study's "adaptive platform" means several treatment candidates can be tested at the same time, with the most promising moving forward and the least promising dropping out, Quantum Leap co-founder Dr. Laura Esserman told Reuters.

"We could have some results in as early as six weeks," she said, adding that additional drugs will soon be added to the roster.

Company officials said Otezla may be able to suppress inflammation from an overactive immune response; Firazyr may help limit fluid in the lungs; and cenicriviroc, which blocks activity of certain immune system cells, could reduce the severity of acute respiratory distress caused by the virus.

The drugs are being dosed in combination with Gilead Sciences Inc's antiviral drug remdesivir and generic steroid dexamethasone, both of which have been shown in rigorous trials to help COVID-19 patients and are now considered to be standard care, Dr. Esserman said. A comparison group of patients will be given remdesivir and dexamethasone alone.

Hospitals have tried other anti-inflammatory drugs in COVID-19 patients, including Regeneron's Kevzara and Roche Holding's Actemra, but trials of both arthritis drugs failed to show effectiveness. Roche is continuing to test Actemra in combination with remdesivir.

The National Institute of Allergy and Infectious Diseases' ongoing adaptive COVID-19 trial is studying remdesivir in combination with Olumiant, an arthritis drug sold by Eli Lilly & Co. Those results are expected next month.

Since the outbreak began seven months ago, so far killing more than 675,000 people worldwide, hundreds of clinical trials have been launched around the world to test whether existing drugs or experimental compounds could be effective treatments.

"There are a huge number of trials that for all the best intentions have been stood up around the world, but many are smaller - what we would call underpowered - and will not provide definitive answers," Amgen's Reese said.

By Deena Beasley

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. -0.11% 87.48 Delayed Quote.-1.07%
AMGEN INC. 0.59% 255.11 Delayed Quote.5.43%
GILEAD SCIENCES, INC. -0.30% 62.9401 Delayed Quote.-2.75%
REGENERON PHARMACEUTICALS -0.71% 555 Delayed Quote.49.08%
ROCHE HOLDING AG 0.36% 316.55 Delayed Quote.0.37%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -3.58% 3744 End-of-day quote.-13.57%
share with twitter share with LinkedIn share with facebook
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
09/29TAKEDA PHARMACEUTICAL COMPANY LIMITE : Ex-dividend day for interim dividend
FA
09/25TAKEDA PHARMACEUTICAL : Announcement of decision on a basic plan for a merger wi..
AQ
09/24TAKEDA PHARMACEUTICAL : phRMA - Coming together to fight COVID-19, A conversatio..
AQ
09/24TAKEDA PHARMACEUTICAL : Announcement of decision on a basic plan for a merger (s..
PU
09/18FOUNDATION MEDICINE : and Takeda Announce Collaboration To Develop FoundationOne..
BU
09/18TAKEDA PHARMACEUTICAL : Presents New Data Highlighting Scientific Advancements i..
BU
09/17PODCAST : Women @ RopesTalk: Conversation With Chika Hirata, Takeda Japan
AQ
09/17TAKEDA PHARMACEUTICAL : to Divest TachoSil to Corza Health for EUR350 Million
AQ
09/17Takeda-led COVID-19 plasma product to begin trial this month
RE
09/16TAKEDA PHARMACEUTICAL : Opens New R&D Cell Therapy Manufacturing Facility to Sup..
AQ
More news
Financials
Sales 2021 3 267 B 30 976 M 30 976 M
Net income 2021 177 B 1 680 M 1 680 M
Net Debt 2021 3 935 B 37 306 M 37 306 M
P/E ratio 2021 44,5x
Yield 2021 4,81%
Capitalization 5 852 B 55 486 M 55 485 M
EV / Sales 2021 3,00x
EV / Sales 2022 2,72x
Nbr of Employees 47 495
Free-Float 99,0%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 443,85 JPY
Last Close Price 3 744,00 JPY
Spread / Highest target 73,6%
Spread / Average Target 45,4%
Spread / Lowest Target 9,51%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Yasuhiko Yamanaka Director
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-13.57%55 486
JOHNSON & JOHNSON2.06%391 975
ROCHE HOLDING AG0.37%293 803
MERCK & CO., INC.-8.80%209 801
PFIZER, INC.-7.68%203 937
NOVARTIS AG-13.05%191 928